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Introduction: The incidence of kidney replacement therapy (KRT) for kidney failure varies internationally
much more than chronic kidney disease (CKD) prevalence. This ecologic study investigated the relation of
CKD prevalence to KRT and mortality risks by world region.
Methods: We used data from Global Burden of Disease and KRT registries worldwide with linear models
to estimate the percentages of variance in KRT incidence and all-cause mortality explained by age-
adjusted prevalence of CKD stages 3 to 5, overall and by gender, in 61 countries classified in 3 regions:
high income (n ¼ 28), Eastern and Central Europe (n ¼ 15), and other (n ¼ 18).
Results: The incidence of KRT ranged from 89 to 378 per million population in high-income regions, 32 to
222 per million population in Central and Eastern Europe, and 22 to 493 per million population in the other
region; age-adjusted CKD prevalence ranged from 5.5% to 10.4%, 7.6% to 13.7%, and 7.4% to 13.1%,
respectively. The relation between these indicators was positive in high-income countries, negative in
Central and Eastern Europe, and null in the other region. Age-adjusted CKD prevalence explained 40% of
the variance in KRT incidence (P< 0.001) in high-income countries. The explained variance of age-adjusted
mortality was close to 0 in high-income countries and positive at 19% (P ¼ 0.10) in Central and Eastern
Europe and at 11% (P ¼ 0.17) in the other region. Results were consistent by gender.
Conclusion: This study raises awareness on the significant part of the gaps in KRT incidence across
countries not explained by the number of individuals with CKD, even in high-income countries where
access to KRT is not limited.
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O
ver the past 2 decades, knowledge about the
epidemiology of chronic kidney disease (CKD) and
its complications has advanced substantially world-
wide.1–6 The increasing availability of national regis-
tries of kidney replacement therapy (KRT) for kidney
failure and the work by the Global Burden of Disease
(GBD) consortium in recent years to search for and
standardize CKD prevalence data from the many
available population-based studies have made it
possible to obtain a global picture of CKD burden
from moderate to advanced stages.7–9 The most striking
finding from these estimates is that the disparities
across countries are much greater for KRT incidence
than for CKD prevalence.
The Global Kidney Health Atlas, led by the Inter-
national Society of Nephrology, recently provided a
comprehensive overview of the capacity of health
systems to deliver care for kidney failure worldwide.10
This capacity remains a major determinant of the var-
iations observed in KRT incidence in low- and middle-
income countries. Large variations in KRT incidence
may also exist, however, across countries where access
to KRT is not restricted. Hallan et al.11 first pointed out
this discrepancy in 2006, showing that KRT incidence
in the United States was 3 times higher than in Nor-
way, despite a similar prevalence of CKD. They sug-
gested that faster progression to kidney failure rather
than a higher number of individuals at risk likely ex-
plains this difference.11 Since then, 2 studies have
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investigated potential explanatory factors for differ-
ences in CKD progression across countries.12,13 Never-
theless, no overview is available of the gaps in KRT
incidence between countries with their links to CKD
prevalence within and across world regions, although
it would help in understanding the possible sources of
variation. We therefore studied the relations of CKD
prevalence with the incidence of KRT for kidney fail-
ure and with all-cause and CKD-related mortality rates
across countries, by region, both overall and by
gender, and estimated the proportion of variance in





Crude (all ages) and age-standardized CKD prevalence
rates in 2016, expressed as percentages, were extracted
overall and by gender from the Global Health Data
exchange, GBD Results Tool website (http://ghdx.
healthdata.org/gbd-results-tool). In the GBD Study,
CKD is defined by an estimated glomerular filtration
rate (eGFR) <60 ml/min per 1.73 m2 or a need for KRT.
Data that inform GBD estimates include microdata or
tabulated data obtained from publications (systematic
literature reviews), as well as other relevant data
sources such as vital registrations, hospital data, and
disease registries (citations available on http://ghdx.
healthdata.org/gbd-2017/data-input-sources). Preva-
lence is estimated with a compartmental model that
allows data to be incorporated for various epidemio-
logic indicators, such as incidence and mortality rates,
through an integrative Bayesian metaregression.14 It is
based on (one or multiple) individual (national repre-
sentative or local) studies or other data sources within a
country. When there are no available data for that
country, modeling may consider information from
other countries with similar epidemiologic back-
grounds. Prevalence estimates were age-standardized
by the GBD 2017 world standard population.14
Incidence of Kidney Replacement Therapy for Kidney
Failure
Kidney replacement therapy included dialysis or pre-
emptive kidney transplantation and its incidence was
expressed per million population (pmp). We used data
gathered by the US Renal Data System from national
KRT registries worldwide that were willing to
contribute data to the international comparison chapter
of this report. We extracted data for the crude inci-
dence of KRT for the year 2016, overall and by gender,
from the US Renal Data System website (https://www.
usrds.org/2018/view/v2_11.aspx). Age-adjusted esti-
mates were not available.7
All-Cause Mortality
Age-standardized all-cause and CKD-related mortality
rates per 100 000 population, overall and by gender,
from 2016 were extracted from the World Health Or-
ganization (WHO), Global Health Estimates website
(http://origin.who.int/healthinfo/global_burden_
disease/estimates/en/).15 WHO 2016 mortality rates are
based on the latest available national-level information
about mortality and causes of death at the beginning of
2018. WHO also uses estimates from the 2016 GBD
study for countries without usable vital registration
data or other nationally representative sources of in-
formation for causes of death.16 CKD-related mortality
included deaths from diabetes-related CKD and from
CKD due to other causes. Mortality rates were age-
standardized according to the WHO 2001 standard
population.17
Global Burden of Disease Regional Classification
System
The 61 countries or regions included in this study,
because of the availability of KRT incidence, were
classified into 3 regions or categories, using GBD super
regions, defined by a combination of geographic loca-
tion and country gross domestic product (GDP), and
based on cause of death patterns (http://www.
healthdata.org/terms-defined), as follows14:
 High-income regions. High-income regions included
those from Asia Pacific (Japan, South Korea, and
Singapore), Australasia (Australia and New Zealand),
Western Europe (Andorra, Austria, Belgium, Cyprus,
Denmark, Finland, France, Germany, Greece, Iceland,
Ireland, Israel, Italy, Luxembourg, Malta,
Netherlands, Norway, Portugal, Spain, Sweden,
Switzerland, and the United Kingdom), Southern
Latin America (Argentina, Chile, and Uruguay), and
North America (Canada and the United States).
 Central and Eastern Europe. This region included
Lithuania, Slovakia, Latvia, Hungary, Russia,
Bulgaria, Romania, Belarus, Serbia, Albania, Bosnia
and Herzegovina, Macedonia, and Ukraine.
 Other regions. Other regions included those from
Latin America (Jalisco [Mexico], Brazil, Peru,
Colombia, and Guatemala), North Africa and Middle
East (Qatar, Saudi Arabia, Kuwait, Iran, Turkey, and
Jordan), South, East, and Southeast Asia (Hong Kong,
Malaysia, Taiwan, Thailand, Philippines, Indonesia,
and Bangladesh), and Southern sub-Saharan Africa
(South Africa).
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Statistical Analysis
Estimates of CKD prevalence (%), KRT incidence
(pmp), and all-cause and CKD-related mortality (per
100,000 population) were tabulated and are presented
as median and ranges according to region, as
described above (high-income, Central and Eastern
Europe, or other), both overall and by gender. To
study the relations with KRT incidence, we plotted
crude KRT incidence rates against crude and age-
adjusted CKD prevalence, by region, overall and by
gender, and for the relations with mortality risk, age-
adjusted all-cause or CKD-related mortality rates
against age-standardized CKD prevalence, again by
region, overall and by gender. In addition, we used
linear regression models to estimate the proportion of
variance (R2) in KRT incidence and mortality rates
explained by CKD prevalence. We tested the linearity
assumption for all regression models, which was not
satisfied for the analysis of the association with mor-
tality rates and required log-transformation. Other
model assumptions (normality of residuals, link
function, and homoscedasticity) were checked with
the Global Validation of Linear Models Assumptions
“glvma” package. Analyses were performed in R
software (version 3.4.2; available at http://www.R-
project.org/).
RESULTS
Geographic Variations in Age-Standardized CKD
Prevalence, by Gender and Region
The age-standardized prevalence of CKD stages 3 to 5
ranged from 5.5% to 10.4% (median 6.3%) in the high-
income region, 7.6% to 13.7% (median 8.7%) in Cen-
tral and Eastern Europe, and 7.4% to 13.1% (median
10.7%) in the other region (Supplementary Table S1).
The prevalence of CKD was higher in women than in
men in all countries except Sweden (Supplementary
Table S2).
Geographic Variations in KRT Incidence, by
Gender and Region
Overall, KRT incidence rates were highest in Taiwan
(493 pmp), the United States (378 pmp), Mexico (355
pmp), and Thailand (345 pmp) and lowest in South
Africa (22 pmp), Ukraine (32 pmp), Bangladesh, and
Belarus (51 pmp). The median KRT incidence was
155 pmp, ranging from 89 to 378 in the high-income
region, 107 pmp ranging from 32 to 222 in Central
and Eastern Europe, and 140 pmp, ranging from 22
to 493 in the other region. The incidence was higher
in men than women in all countries but one, with
sex ratios ranging from 1.04 in Bulgaria to 2.5 in
Estonia. In Jordan, more women (70 pmp) than men
(51 pmp) received treatment for KRT.
Geographic Variations in Age-Adjusted All-
Cause and CKD-Related Mortality Rate, by
Gender
The age-standardized all-cause mortality rate per
100,000 ranged from 299 in Japan to 555 in Argentina
in the high-income region (median 360), from 525 in
Estonia and Bosnia Herzegovina to 798 in Russia in
Central and Eastern Europe (median 647), and from 523
in Qatar to 1213 in South Africa in the other region
(median 640; Supplementary Table S3). All-cause mor-
tality rates were higher in men than in women in all
countries (Supplementary Table S4), with sex ratios
ranging from 1.15 in Kuwait to 2.2 in Lithuania. The
age-standardized CKD-related mortality rate ranged
from 2.5 to 42.4 per 100,000 in the high-income region,
from 3.5 to 17 in Central and Eastern Europe, and from
2.6 to 45.2 in the other region.
Ecologic Associations Between Age-Adjusted
CKD Prevalence and KRT Incidence
In the high-income region, there was a positive and
statistically significant relation between the age-adjusted
prevalence of CKD and KRT incidence (Figure 1). CKD
prevalence explained 40% of the variation in KRT
incidence, while 60% remained unexplained. Relations
were similar when crude CKD prevalence was used
(Supplementary Figure S1). In a subset of the 23 (of the
28 studied) high-income countries with available KRT
incidence data stratified by gender, the percentage of
explained variance was slightly lower in men than
women (49% vs. 56%; Supplementary Table S5). In
Central and Eastern Europe, KRT incidence was nega-
tively and statistically significantly related to both the
crude and age-adjusted prevalence of CKD and did not
differ by gender. In contrast, in countries from the other
region, crude CKD prevalence was positively and
significantly related to KRT incidence (explained
variance ¼ 37%; P ¼ 0.007), but the relation was null
with age-standardized prevalence.
Although differences in KRT incidence between
countries with similar CKD prevalence were usually
larger across than within regions, substantial intrare-
gional variations were also observed. Western Europe
is the region with the smallest differences across
countries, but KRT incidence was nonetheless 3 times
higher in Greece than in Iceland despite their similar
CKD prevalence. In South, East, and Southeast Asia,
KRT incidence varied from 1 to 10, for small differences
in CKD prevalence.
Ecologic Associations Between Age-Adjusted
CKD Prevalence and Mortality Risk
In the high-income region, CKD prevalence explained a
low percentage of the variation in mortality (2%),
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while it tended to explain a higher but still not sig-
nificant percentage in Central and Eastern Europe and
in the other region (Figure 2). This percentage was
similar for both genders in the high-income and other
regions, but differed strongly by gender, 47% in men
versus 0% in women, in Central and Eastern Europe
(Supplementary Table S5). Regarding CKD-related
mortality, the association was positive and statisti-
cally significant (P ¼ 0.016) in high-income countries,
negative (P ¼ 0.042) in Central and Eastern Europe,
and positive but nonsignificant (P > 0.10) in the other
region (Supplementary Figure S2).
DISCUSSION
We confirm the well-known greater gaps in KRT inci-
dence than in CKD prevalence between countries in all
the GBD regions. The main novelty of this study is to
highlight the high percentage of variation in KRT
incidence not explained by the prevalence of CKD,
even in high-income countries (60%) where access to
dialysis is not restricted. For similar CKD prevalence,
KRT incidence rate can be up to 3 times higher from
one country to another, as between Iceland and Greece.
These results also show an unexpected negative asso-
ciation between these 2 kidney health indicators in
Central and Eastern Europe, together with a weak but
positive association of CKD prevalence with all-cause
mortality. An overview of these ecologic associations
we observed can help raise global awareness about the
issues and challenges regarding kidney failure pre-
vention and care.
Our results extend worldwide the observation of
significant discrepancies in the KRT to CKD ratio be-
tween countries, as described previously between
Norway and the US white population.11 Only a small
fraction of individuals with CKD eventually progress to
kidney failure, but if the variation in the number of
individuals with CKD were the only explanation for
that of KRT incidence, the ratio of KRT incidence to
CKD prevalence would be similar across countries, and
the percentage of variance explained would be 100%.
In high-income countries, this percentage was 40%,
which suggests that differences in the distribution of
CKD risk factors play a substantial role in the variation
of kidney failure incidence between countries. None-
theless, although a meta-analysis of 19 general
population-based studies from 13 European countries
did find variations in CKD prevalence across these
countries, differences in major CKD risk factors,
including diabetes, hypertension, and obesity, did not
appear to explain them well.6,8,18–20 The negative
relation or lack of association observed in Central and
Eastern Europe and in the other region, in contrast,
cannot be interpreted as the absence of an impact of
CKD risk factors, especially given that CKD prevalence
is higher in these regions than in high-income coun-
tries.6,8,18–20 In Central and Eastern Europe, the asso-
ciation of higher CKD prevalence with lower KRT
incidence together with higher all-cause mortality may
Figure 1. Incidence of kidney replacement therapy (KRT) according to age-standardized chronic kidney disease (CKD) prevalence, by region.
pmp, per million population.
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instead reflect the combination, at the population level,
of poor population health with a health care system
with inadequate capacity. Several CKD risk factors are
well established, including genetic, socioeconomic, and
environmental risk factors, as well as poor maternal
and fetal health. A landmark article reporting the
conclusions of an International Society of Nephrology
CKD summit on Global Kidney Health in 2016 updated
these factors, which are summarized in Table 1.1,21
These risk factors might be attenuated by promoting
healthy lifestyles, improved education of the public
and of health practitioners, and strategies to improve
maternal and fetal health.
Although heterogeneity in the prevalence of CKD
risk factors explains part of the variance in KRT inci-
dence, this study shows that a significant part of this
variance remains unexplained. Several hypotheses can
be generated, including variations across countries in
risk factors for CKD progression or in access to KRT
(Table 1). Hallan et al.11 first suggested that slower
progression to kidney failure rather than a smaller
number of individuals could account for the lower
incidence of KRT in Norway than in the United States.
Two recent meta-analyses of CKD cohort studies have
investigated this hypothesis with individual-level
data.12,13 The European CKD Burden Consortium,
which used a joint model to compare estimated eGFR
decline and mortality risk across 9 cohorts from 5 Eu-
ropean countries, showed that baseline patient profiles
and CKD progression rates differed substantially be-
tween studies.12,13 These variations in CKD
progression, however, persisted despite adjustment for
baseline eGFR, age, sex, albuminuria, comorbidities,
and use of renin-angiotensin system inhibitors. The
international network of CKD cohort has also observed
different baseline profiles and highly heterogeneous
risks of CKD progression, KRT incidence, and mortality
among individuals with CKD participating in 8 cohort
studies around the globe.12,13 This study also observed
that adjustment for several patient characteristics and
laboratory markers did not substantially attenuate the
differences in outcomes. Its finding that the magnitude
of the associations of individual-level predictors with
clinical outcomes varied substantially across studies
suggests that the setting or differences in populations
may influence these differences. Another international
network of CKD cohorts study finding of considerable
heterogeneity in blood pressure control and antihy-
pertensive prescription patterns in CKD worldwide also
indicates that clinical practices may have an effect.22,23
Finally, because kidney failure incidence is assessed
from dialysis and transplantation registries, factors
linked to the management of transition to kidney fail-
ure or access to KRT may play a major role in the gaps
observed between countries (Table 1). It is well-known
that access to KRT is influenced by local policies and
that several countries, such as the United States, Japan,
South Korea, and Taiwan, have liberal criteria for
acceptance on dialysis, while many European coun-
tries, Australia, and New Zealand have a less liberal
acceptance policy and most African, Asian, and Central
or Eastern European countries have limited access. An
Figure 2. Age-standardized all-cause mortality according to age-standardized chronic kidney disease (CKD) prevalence, by region.
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ecologic study of 46 countries reported that GDP per
capita and percentage of GDP spent on health care were
independently associated with KRT incidence.3,4,10,13,24
It also showed that in more developed countries, the
private for-profit share of hemodialysis facilities was
also associated with higher KRT incidence. This study
and ours raise the issue of overtreatment related to
early-start dialysis in countries with extremely high
KRT incidence. In France, eGFR level at dialysis start
explained a substantial part of the variations in KRT
incidence between regions.25 Variations in the avail-
ability of conservative therapy may also have an impact
in the elderly population, as suggested by the Global
Kidney Health Atlas study.10,26 Overall, these meta-
analyses highlight the complexity of the relations be-
tween CKD and KRT risk and the need for further
investigation.
This study has several strengths including the large
number of countries spread over the different GBD
super regions with standardized estimates of kidney
health indicators. Another strength is that we were
able to assess the relations between CKD prevalence
and KRT incidence by gender in many of these coun-
tries. We also looked at the relation between CKD
prevalence and all-cause and CKD-related mortality
risk, a major competing risk for KRT in CKD.
Our study also has a number of limitations. First, it
is an ecologic study, and the associations observed at
the country level may be different at the individual
level. Further studies comparing the relationship of
CKD to kidney failure risk at the individual level are
needed to identify potentially modifiable risk factors
and racial disparities. Second, the use of KRT registry
data did not enable us to describe the association of
CKD prevalence with kidney failure risk because KRT
registries cannot capture patients who progress to
kidney failure but do not have access to KRT, refuse
dialysis, or receive conservative care. Moreover, age-
standardized KRT incidence was not available. Third,
CKD prevalence may have been affected by the use of
different creatinine assays or GFR estimation equations
across studies,6,8,18–20 although the GBD correction
methods should have reduced these disparities by
standardizing these estimates. Fourth, the available
reference population for age standardization was
different for the WHO and the GBD statistics. How-
ever, while this may have had an impact on mortality
rate and CKD prevalence estimates, it should not have
affected the associations we observed. Finally, the ag-
gregation of countries with diverse CKD epidemiology
in one single “other” group may be controversial, but
the small number of these countries precluded a more
detailed stratification.
In conclusion, this ecologic study highlights the
large proportion of the global variation in KRT inci-
dence that is apparently not explained by the number
of individuals with CKD. While differences in health
care resources are an obvious explanation of disparities
in access to KRT, at least in part, in low- and middle-
income countries, other hypotheses should be
assessed for high-income countries, such as variations
in clinical practice patterns intended to slow CKD
progression or to manage the transition to KRT.27,28
The issue of dialysis overtreatment is scarcely dis-
cussed and may receive greater attention from both the
patients and public health perspective. International
comparisons at both patient and provider levels are
necessary to investigate the relative impact of indi-
vidual characteristics, physician practices, and local
policies on the incidence of KRT.
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Table 1. Potential sources of international variations in the relation
between chronic kidney disease prevalence and the risk to progress
to kidney failure requiring kidney replacement therapy
Variation in methods to estimate CKD prevalence
, Sampling method and sample representativeness of country population
, Creatinine assay and GFR estimating equation
Variations in life expectancy and distribution of CKD risk factors
Life expectancy
, Competing risk of mortality
Heterogeneity in the prevalence of CKD risk factors
, Ethnicity and race
, Genetic risk factors
, Environmental risk factors
- Socioeconomic factors and working conditions
- Lifestyle, diet, and access to clean water
- Obesity, diabetes, and hypertension
- Nephrotoxic medications, herbal remedies, and environmental
nephrotoxins
- Infections
, Poor maternal and fetal health (low birth weight and premature birth)
Acute kidney injury as a risk factor for CKD
Variation in risk factors for CKD progression (GFR decline) to kidney failure
, Variation in risk factors for CKD progression
- Albuminuria
- Diabetes and hypertension
- Lifestyle (smoking status and physical activity)
, Acute-on-CKD as a risk factor for CKD progression
, Heterogeneity in clinical practices
- Use of ACEIs/ARBs and blood pressure control
- Dietary counseling (sodium and protein)
Variations in access to KRT
, Variations in health care resources
- GDP
- Health expenditure as % GDP
- Private vs. public share of health expenditure
- Fee for service
- Out of pocket expenses
, Practice pattern regarding initiation of KRT
- GFR at dialysis initiation (early vs. late dialysis start)
- Conservative therapy for elderly patients with CKD
ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers;
CKD, chronic kidney disease; GDP, gross domestic product; GFR, glomerular filtration
rate; KRT, kidney replacement therapy.
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